$2.40 Million in Sales Expected for Curis, Inc. (CRIS) This Quarter

Wall Street analysts predict that Curis, Inc. (NASDAQ:CRIS) will post $2.40 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Curis’ earnings. The lowest sales estimate is $2.29 million and the highest is $2.50 million. Curis posted sales of $3.26 million during the same quarter last year, which suggests a negative year over year growth rate of 26.4%. The company is scheduled to announce its next quarterly earnings results on Thursday, March 14th.

On average, analysts expect that Curis will report full year sales of $10.19 million for the current year, with estimates ranging from $9.97 million to $10.40 million. For the next financial year, analysts expect that the business will post sales of $10.79 million, with estimates ranging from $9.48 million to $12.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Curis.

Get Curis alerts:

Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.09. The business had revenue of $2.85 million for the quarter, compared to the consensus estimate of $2.38 million. Curis had a negative return on equity of 299.20% and a negative net margin of 316.98%.

Several research analysts have recently commented on CRIS shares. Zacks Investment Research raised Curis from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Wednesday, August 8th. Cowen reissued a “buy” rating on shares of Curis in a report on Monday, August 6th. Finally, SunTrust Banks reduced their target price on Curis to $8.00 and set a “buy” rating on the stock in a report on Friday, August 3rd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $13.33.

Shares of CRIS traded down $0.11 on Monday, hitting $1.56. The company’s stock had a trading volume of 220,084 shares, compared to its average volume of 301,291. The company has a market capitalization of $52.65 million, a P/E ratio of -0.87 and a beta of 1.16. The company has a debt-to-equity ratio of 38.74, a current ratio of 2.63 and a quick ratio of 2.63. Curis has a fifty-two week low of $1.36 and a fifty-two week high of $7.17.

Several institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in shares of Curis by 780.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 73,954 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 65,554 shares in the last quarter. LMR Partners LLP acquired a new position in shares of Curis in the 2nd quarter worth approximately $124,000. Paloma Partners Management Co acquired a new position in shares of Curis in the 2nd quarter worth approximately $223,000. Finally, Millennium Management LLC acquired a new position in shares of Curis in the 2nd quarter worth approximately $540,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.